Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Potential Rise

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton Feb 06, 2023 3:40pm

278 Views

Post# 35270108

RE:RE:RE:RE:RE:Potential Rise

As a thought experiment, if we assume 12 of the 14 questionable patients were not CR or IR and we remove them from consideration at 450 days, we are left with 8 CRs out of 17 evaluable patients or 47% at 450 days. Further, if the 3 IR patients at 450 days are recalculated as CR we would have a 450 day CR rate of 65% - which, (admittedly coincidentally) is the same as the phase 1 results ( 63% CR in 2 out of 3 full dose patients)

enriquesuave wrote:
Well stated. As well I think we can really count 14 or at least 13 invalid patients from 1st set of 29. As 12 were severely undertreated, but afterwards 1 patient who died of HF was counted as NR, and 1 of the 3 patients from PH1 was also not given an optimized treatment and was probably invalid due to metastatic disease unrelated to bladder. All IMO, so 13 or 14 out of 29 patients are not really representative of our treatment. But still we are beating every single agent out there.

Eoganacht wrote: Hi consultant99 - with all of the BCG-unresponsive NMIBC treatments we have been talking about on this board the initial CR rate declines over time.

But there is more going on with our trial that further explains the CR drop at 450 days.

Of our 43 evaluable patients at 90 days 53% exhibited a complete response. The 12 initially undertreated patients represent 23% of these 43 evaluable patients.

But as the trial progresses, these 12 undertreated patients represent an increasingly larger percentage of the total patients evaluated.

Of our 29 evaluable patients at 450 days 28% exhibited a complete response. The 12 initially undertreated patients represent 41% of these 29 evaluable patients.

Over time our CR percentage at both 90 days and 450 days should improve as the initially undertreated 12 patients become an increasingly smaller percentage of evaluable patients.

consultant99 wrote: Interesting point raised about more than 2 treatments.

I have wondered if any patients so far that were NR after their first treatment achieved PR or CR after a second treatment. If not is this a limitation for the technology

I also wonder why after 450 days the CR rate drops below the 90 day level even though patients that did achieve CR go through a second treatment.

I thought there was the potential for an immune response; I wonder what the outcome was for those patients in the trial after 450 days.. Would the company or the FDA have access to the information?